- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
February 22, 2021Robins Kaplan Expands Health Care Litigation Group
-
February 1, 2021Meegan Hollywood Selected to Join American Antitrust Institute Advisory Board
-
January 28, 2021Human Rights Campaign Names Robins Kaplan LLP a “Best Place to Work for LGBTQ Equality” for the Thirteenth Consecutive Year
-
February 26, 2021Key Decisions Affecting Drug and Device Litigation in the Last Year
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
February 25, 2021Financial Daily Dose 2.25.2021 | Top Story: McKinsey Ousts Managing Partner on Heels of Opioid Settlement
-
February 24, 2021Financial Daily Dose 2.24.2021 | Top Story: Chair Powell Promises Continued Fed Support for US Economy
-
February 23, 2021Financial Daily Dose 2.23.2021 | Top Story: SoftBank Nears Deal With WeWork’s Neumann for $500M Share Purchase
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Trial Court Rules In Favor of Novel Labs. Invalidating Three Patents and Federal Circuit Summarily Affirms
Represented Novel Laboratories, Inc., a pharmaceutical company seeking to market a generic version of Intermezzo®. Intermezzo® is a sublingual formulation of zolpidem indicated for middle-of-the-night insomnia. Following a 10-day bench trial, Chief Judge Linares found in favor of our client, ruling that the asserted claims of all three patents-in-suit were invalid as obvious. The Federal Circuit confirmed the invalidity findings in a summary affirmance. LMG Life Sciences named this case one of the Hatch-Waxman Impact Cases of the Year in 2016. Purdue Pharm. v. Actavis Elizabeth LLC, 15-1659 (Fed. Cir.); Purdue Pharm. Products LP v. Actavis Elizabeth LLC, 12-5311 (D.N.J.).
Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.
Similar Results
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.